Predict your next investment

INDUSTRIAL | Manufacturing / Laboratory & Research Equipment Manufacturing
bioquell.com

See what CB Insights has to offer

Stage

Acq - P2P | Acquired

Valuation

$0000 

About Bioquell

Bioquell (LSE: BQE) is a provider of hydrogen peroxide vapor bio-decontamination systems and services for the life sciences and healthcare industries.

Bioquell Headquarter Location

52 Royce Cl

Andover, England, SP10 3TS,

United Kingdom

+44 (0)1264 835 835

Latest Bioquell News

Sodexo, Ecolab Link Up to Reduce Hospital-Associated Infections

Sep 7, 2021

Facility management provider Sodexo announces an expanded partnership with water, hygiene, and infection prevention solutions and services provider Ecolab Inc. Together, they will deliver a new infection prevention offering for hospitals and healthcare facilities across the U.S. Sodexo’s program, Protecta Plus, provides an additional solution to help reduce the risk of infection with Ecolab’s Bioquell hydrogen peroxide vapor technology. Protecta Plus offers hospitals technology solutions for their specialized disinfection needs. It provides personalized support and fully managed services with dedicated infection prevention specialists. Protecta Plus also supports Sodexo’s foundational Protecta offering, a standardized, integrated environmental infection program. The program is designed for organizations looking to reduce or stabilize hospital-associated infections (HAIs) and keep them low. “We’re excited to add this to the Protecta Plus lineup,” says Brooke Hossfeld, MPH, CIC, MLS (ASCP) CM, infection prevention specialist for Sodexo. “The broad efficacy of a sterilant is great because hospitals face such a wide range of challenges—from typical organisms like MRSA and C.diff, as well as emerging issues such as COVID-19 variants to C. auris—they need to be ready for almost anything.” Bioquell Hydrogen Peroxide Sterilant is an EPA-registered sterilant that uses an automated process to decontaminate enclosed spaces. It reaches all exposed surfaces—including hard-to-reach ceilings, far corners, and open drawers for maximum impact. The proprietary technology is proven effective against even tough organisms, such as bacterial spores. With Bioquell, Sodexo’s Protecta Plus can be implemented within a variety of service models to provide critical aid in the fight against HAIs in different care settings. “Some patients are especially vulnerable to HAIs,” says Kristen Gray, Ecolab area vice president for life sciences. “Having this sterilant technology to kill viruses, spores, fungi, and bacteria where these patients are treated and heal—burn units, cancer centers, operating rooms, children’s hospitals, and ICUs—is something we’re very proud of. We offer options to all types of facilities, with the option for on-site environmental service teams to run this technology or Ecolab experts who can provide onsite turnkey services.” Share:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Bioquell

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Bioquell is included in 1 Expert Collection, including Infectious Disease.

I

Infectious Disease

2,222 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

Bioquell Patents

Bioquell has filed 9 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/14/2013

2/20/2018

Surgical instruments, Experimental cancer drugs, Engine technology, Antineoplastic drugs, Fluoroarenes

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/14/2013

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

2/20/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Surgical instruments, Experimental cancer drugs, Engine technology, Antineoplastic drugs, Fluoroarenes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.